West Pharmaceutical
695 hedge funds and large institutions have $24B invested in West Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 126 funds opening new positions, 246 increasing their positions, 218 reducing their positions, and 55 closing their positions.
149% more call options, than puts
Call options by funds: $60.1M | Put options by funds: $24.1M
129% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 55
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
48% more capital invested
Capital invested by funds: $16.2B → $24B (+$7.83B)
13% more repeat investments, than reductions
Existing positions increased: 246 | Existing positions reduced: 218
9% more funds holding
Funds holding: 637 → 695 (+58)
0.74% more ownership
Funds ownership: 92.97% → 93.72% (+0.74%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$274M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$159M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$158M |
| 4 |
JP Morgan Chase
New York
|
+$105M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$66.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$144M |
| 2 |
Two Sigma Investments
New York
|
-$94.8M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$76.1M |
| 4 |
Renaissance Technologies
New York
|
-$69.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$61.3M |
WST Hedge Fund Activity: Q1 2023 in Review
695 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q1 2023, worth a combined $24B — up 48% from $16.2B a quarter earlier.
Buyers outnumbered sellers: 126 funds opened new WST positions and 55 closed out — a net gain of 71 holders — while 246 added to existing stakes and 218 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $274M. The largest seller was Fidelity Investments, cutting an estimated $144M.
- 695 institutional investors held West Pharmaceutical (WST) as of Q1 2023, up from 637 in Q4 2022.
- Funds reported $24B of West Pharmaceutical stock for Q1 2023, up 48% quarter-over-quarter.
- 126 funds opened new West Pharmaceutical positions in Q1 2023 and 55 closed out, a net change of +71 holders.
- The largest West Pharmaceutical buyer in Q1 2023 was Citadel Advisors, an estimated $274M added.
- The largest West Pharmaceutical seller in Q1 2023 was Fidelity Investments, an estimated $144M sold.
Based on aggregated 13F filings for Q1 2023.